Compare DINO & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DINO | RDY |
|---|---|---|
| Founded | 1947 | 1984 |
| Country | United States | India |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.2B | 11.6B |
| IPO Year | 2022 | 2001 |
| Metric | DINO | RDY |
|---|---|---|
| Price | $59.36 | $12.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 1 |
| Target Price | ★ $61.18 | $16.90 |
| AVG Volume (30 Days) | 1.9M | ★ 2.0M |
| Earning Date | 05-01-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.36% | 0.56% |
| EPS Growth | ★ 238.46 | N/A |
| EPS | ★ 3.08 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.01 | $7.72 |
| Revenue Next Year | N/A | $3.50 |
| P/E Ratio | $19.37 | ★ $18.67 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $29.23 | $12.79 |
| 52 Week High | $64.70 | $16.17 |
| Indicator | DINO | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 51.86 | 38.78 |
| Support Level | $47.04 | N/A |
| Resistance Level | $64.70 | $14.14 |
| Average True Range (ATR) | 2.15 | 0.25 |
| MACD | -0.26 | -0.02 |
| Stochastic Oscillator | 50.07 | 10.84 |
HF Sinclair is an integrated petroleum refiner that owns and operates seven refineries serving the Rockies, midcontinent, Southwest, and Pacific Northwest, with a total crude oil throughput capacity of 678,000 barrels per day. It can produce 380 million gallons of renewable diesel annually. It holds a marketing business with over 300 distributors and 1,500 wholesale branded sites across 30 states. It also owns and operates 4,400 miles of petroleum product pipelines and terminals principally in the southwestern United States.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.